ScreenPoint Medical develops AI technology that assists radiologists in the early detection and diagnosis of breast cancer.<h3>AI Systems Are Indispensable for Improving Healthcare</h3>The company was founded in 2014 as a spin-off from Radboud UMC. In 2018, ScreenPoint was the first to commercially release deep learning technology for breast cancer detection on 2D and 3D mammograms as a medical device, in both Europe and the U.S. 1Today, ScreenPoint’s AI software is used worldwide. In 2023 alone, for example, more than 2 million mammograms in over 40 countries worldwide were analyzed using ScreenPoint’s AI system. A Swedish population-based screening study examined the system’s effectiveness, showing that doctors using the software detect 30% more cases of cancer that would otherwise be missed. 2,3 With more than 30 peer-reviewed publications to date on the use of the AI system in various countries with different populations and mammography devices, irrefutable evidence is being built that AI systems are indispensable for improving and personalizing care and for managing the increasing workload.At ScreenPoint Medical, we are constantly striving to push the boundaries to further improve AI systems and make them more widely applicable. That is why we are not only working to improve our current AI systems using the latest technological advancements and datasets, but also developing new systems to enhance support for other clinical modalities, applications, and integration within the clinic. In this way, we contribute to our mission of providing women worldwide with access to affordable, high-quality care, detecting breast cancer earlier, improving patient outcomes, and thereby mitigating the impact of breast cancer. Founder: Prof. Nico Karssemeijer, Sir John Michael Brady

Sector

Health

screenpoint medical2.jpg

ScreenPoint Medical

ScreenPoint Medical develops AI technology that assists radiologists in the early detection and diagnosis of breast cancer. 